A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Dulaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 23 Jun 2018 Data will be presented at the American Diabetes Association's (ADA) 78thScientific Sessions 2018, according to an Eli Lilly and Co. media release.
    • 23 Jun 2018 Primary endpoint (Change from Baseline in Hemoglobin A1c (HbA1c)) has been met, according to an Eli Lilly and Co. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top